Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287150 · ClinicalTrials.gov registry record · Phase 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
10
Study locations

NCT07287150 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 100 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (49% lower). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287150, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
10
Study locations

Study Summary

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Enzalutamide
  • DRUG Abiraterone
  • DRUG Inavolisib
  • DIAGNOSTIC_TEST Diagnostic test

Study Locations (10)

Other

  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University Health System - Seoul
  • Asan Medical Center. - Seoul
  • Samsung Medical Center - Seoul

Iowa

  • Holden Comprehensive Cancer Center - Iowa City

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Queensland

  • Sunshine Coast University Hospital - Birtinya

Victoria

  • Box Hill Hospital - Box Hill

São Paulo

  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia - Santo André

Quebec

  • Jewish General Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-03-31
Est. Completion 2029-07-30
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07287150

The ClinicalTrials.gov registry entry for NCT07287150 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT07287150 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Other, Iowa, South Carolina.

Frequently Asked Questions

What is clinical trial NCT07287150 about?

NCT07287150 is a clinical study titled "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer". This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) wh...

What is the current status of trial NCT07287150?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-03-31. Estimated completion is 2029-07-30.

What conditions does trial NCT07287150 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT07287150?

The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Inavolisib (DRUG), Diagnostic test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07287150?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287150 being conducted?

This trial has 10 study locations across Iowa, South Carolina, Queensland, Victoria, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.